Pallas Capital Advisors LLC Buys New Shares in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Pallas Capital Advisors LLC acquired 8,535 shares of Kiniksa Pharmaceuticals International valued at approximately $236,000 during the second quarter, indicating interest from institutional investors.
• Insider selling occurred, notably with CAO Michael R. Megna selling 17,000 shares and COO Eben Tessari selling 138,614 shares, representing significant decreases in their holdings.
• Kiniksa Pharmaceuticals reported $0.23 EPS for the last quarter, exceeding analyst expectations, and is projected to have a consensus target price of $41.17 according to market analysts.

Pallas Capital Advisors LLC bought a new position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,535 shares of the company's stock, valued at approximately $236,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Wealth Enhancement Advisory Services LLC purchased a new position in Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $301,000. GAMMA Investing LLC boosted its position in shares of Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after buying an additional 568 shares during the period. Deutsche Bank AG boosted its position in shares of Kiniksa Pharmaceuticals International by 177.1% in the first quarter. Deutsche Bank AG now owns 394,522 shares of the company's stock worth $8,762,000 after buying an additional 252,125 shares during the period. Victory Capital Management Inc. purchased a new stake in Kiniksa Pharmaceuticals International in the 1st quarter worth about $1,184,000. Finally, Nuveen Asset Management LLC lifted its stake in Kiniksa Pharmaceuticals International by 7.3% in the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after acquiring an additional 54,361 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Insider Buying and Selling

In related news, CAO Michael R. Megna sold 17,000 shares of the firm's stock in a transaction on Monday, August 4th. The stock was sold at an average price of $32.35, for a total transaction of $549,950.00. Following the completion of the sale, the chief accounting officer directly owned 33,041 shares of the company's stock, valued at $1,068,876.35. This trade represents a 33.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Eben Tessari sold 138,614 shares of the stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $33.20, for a total value of $4,601,984.80. Following the sale, the chief operating officer owned 49,915 shares in the company, valued at $1,657,178. The trade was a 73.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 561,371 shares of company stock valued at $18,825,009 in the last ninety days. 53.48% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals International Stock Up 1.9%

Shares of NASDAQ KNSA opened at $36.08 on Tuesday. The business's 50 day moving average is $32.77 and its two-hundred day moving average is $27.80. The company has a market cap of $2.67 billion, a P/E ratio of 902.23 and a beta of 0.20. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.82 and a 12 month high of $37.34.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. The firm had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Wells Fargo & Company increased their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Wedbush reiterated an "outperform" rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Jefferies Financial Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Finally, Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 7th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of "Buy" and a consensus target price of $41.17.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.